Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373360 · ClinicalTrials.gov registry record · Phase 4
Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin
A Phase 4 study, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT00373360 is a Phase 4 study that has completed, run by United Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT00373360, a Phase 4 study, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life.
Interventions
- DRUG treprostinil sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00373360
The ClinicalTrials.gov registry entry for NCT00373360 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which treprostinil sodium is the first listed.
NCT00373360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00373360 about?
NCT00373360 is a clinical study titled "Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin". The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life.
What is the current status of trial NCT00373360?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2006-09. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00373360?
The interventions under investigation include: treprostinil sodium (DRUG).
Who is sponsoring clinical trial NCT00373360?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.